Sign in to view content

Evaluating Intravitreal ANX007, a Novel C1q Inhibitor, in the Treatment of GA Secondary to AMD: The ARCHER Study

David S. Boyer, MD

Video
Published 2021

Related

Comparison of CRISPR-based Genome Editing of VEGF-A as Treatment Strategy for Choroidal Neovascularization
Glenn C. Yiu, MD, PhD
Updates from the Field
2019
Assessing Commercially Available Cell Therapies for Retinal Disease in the U.S.
Ajay E Kuriyan, MD, MS
Daniel Simhaee, MD
Updates from the Field
2018
Episode 119: 2018 ASRS Annual Meeting Post-Mortem Including Protocol S 5-Year Results
Jayanth Sridhar, MD
Member Podcasts
2018

Category: AMD-Non-neovascular

See more